Back to Search Start Over

Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX).

Authors :
Pupillo, Elisabetta
Bianchi, Elisa
Beghi, Ettore
Pedrazzini, Francesco Andrea
Giglio, Angela
Schilke, Edoardo Dalmato
Percetti, Marco
Colleoni, Carlo Morotti
Mainini, Gabriele
Calabresi, Paolo
Primiano, Guido
Frisullo, Giovanni
Padovani, Alessandro
Cristillo, Viviana
Pilotto, Andrea
Arici, Davide
Gipponi, Stefano
Tedeschi, Gioacchino
d'Ambrosio, Alessandro
Melisi, Rosario Domenico
Source :
Scientific Reports. 2/4/2025, Vol. 15 Issue 1, p1-9. 9p.
Publication Year :
2025

Abstract

The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design. Vaccination exposure was compared between individuals with a first diagnosis of a neurological disorder (cases) and age- and sex-matched controls. A total of 624 participants were enrolled, and after random 1:1 matching 265 cases and 265 matched controls (total 530 participants) were included in the analyses. The most frequent neurological diagnosis in cases were stroke (60.4%), multiple sclerosis (11.3%) and seizures (6.4%). The proportion of vaccinated participants was 72.1% among cases and 79.6% among controls. A protective role of vaccination on the risk of developing a new neurological disorder was detected in the unadjusted analysis (OR 0.50; 95% CI 0.29–0.86; p = 0.0114). After adjustment for confounders, the number of vaccination doses received was associated with a reduced risk of developing new neurological disorders for participants aged over 60 years (p = 0.0472; OR 0.14, 95% CI 0.03–0.68), with pre-existing comorbidities (p = 0.0122; OR 0.04, 95% CI 0.01–0.99) and for stroke (p = 0.0232; OR 0.04, 95% CI 0.02–0.97). The COVIVAX study provided no warning sign regarding an increase in the risk of developing new neurological disorders following COVID-19 vaccination of any type or doses. A potentially protective effect of multiple doses of COVID-19 vaccines against the risk of stroke in people aged over 60 needs to be confirmed by further studies. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20452322
Volume :
15
Issue :
1
Database :
Academic Search Index
Journal :
Scientific Reports
Publication Type :
Academic Journal
Accession number :
182845248
Full Text :
https://doi.org/10.1038/s41598-025-88837-0